Coherus BioSciences, Inc. (CHRS)
After hours:
| Previous close | 2.1200 |
| Open | 2.1700 |
| Bid | 1.8800 x 800 |
| Ask | 1.9100 x 500 |
| Day's range | 1.8100 - 2.1800 |
| 52-week range | 1.4300 - 5.6300 |
| Volume | |
| Avg. volume | 2,238,037 |
| Market cap | 215.646M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.5300 |
| Earnings date | 31 Jul 2024 - 05 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 10.43 |
Insider MonkeyCoherus BioSciences, Inc. (NASDAQ:CHRS) Q1 2024 Earnings Call Transcript
Coherus BioSciences, Inc. (NASDAQ:CHRS) Q1 2024 Earnings Call Transcript May 10, 2024. CHRS isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Ladies and gentlemen, thank you for standing by. At this time, I would like to welcome everyone to Coherus […]
ZacksCoherus BioSciences (CHRS) Reports Q1 Loss, Misses Revenue Estimates
Coherus BioSciences (CHRS) delivered earnings and revenue surprises of -540% and 24.45%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
GlobeNewswireCoherus BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update
– Net revenue of $77.1 million in Q1 2024 – – CRI and ENB Therapeutics development partnership for toripalimab in ovarian cancer – – New debt and royalty financing replaces $75 million term loan, with debt maturity of May 2029 – – Conference call today at 5:00 p.m. Eastern Time – REDWOOD CITY, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), today reported financial results for the quarter ended March 31, 2024 and recent business highlights: RECENT BUSI
